Biotherapeutics Company Initiates Partnership For Lung Cancer Treatment

Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has entered into a collaboration with SIGA Technologies (Nasdaq: SIGA). This partnership, initiated in the first quarter of 2024, aims to accelerate the development of Calidi’s revolutionary RTNova (CLD-400) virotherapy platform. The collaboration represents a significant step toward potentially providing a universal treatment for all tumor types, initially focusing on lung cancer and metastatic solid tumors, which together account for the majority of cancer-related deaths. $Calidi Biotherapeutics(CLDI.US)$